You are viewing: Ksa Biobanking Market analysis
Part of: Biobanking Market (Global)

The Ksa Biobanking Market was valued at $44.8 Million in 2025 and projected to reach to $59 Million by 2030, representing a compound annual growth rate of 5.6%. KSA's biobanking market is positioned for steady expansion driven by healthcare modernization initiatives and increased focus on research and development capabilities.

Ksa Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Ksa Biobanking Market Trends and Insights

  • Ksa's biobanking sector is benefiting from increased investment in healthcare infrastructure, rising prevalence of chronic diseases, and growing adoption of precision medicine initiatives across the region.
  • The market in Ksa reflects strong government support for life sciences research and development, positioning the country as a key player within the GCC biobanking landscape. Ksa's biobanking expansion is underpinned by enhanced regulatory frameworks and collaboration between public and private healthcare institutions.
  • Throughout the 2025–2030 forecast period, Ksa is expected to see accelerated demand for sample storage, diagnostic services, and biorepository management solutions.
  • The market growth in Ksa is also driven by increasing clinical trial activities and the establishment of specialized biobanking facilities that support genomic research and personalized medicine applications..

Key Market Statistics

  • CAGR (2025-2030) 5.6% CAGR
  • Market Size, 2025 ~USD 44.8 Million
  • Forecast, 2030 ~USD 59 Million
  • Country Ksa

Ksa Biobanking Market Overview

Market Size & Growth :

KSA's biobanking market is valued at USD 44.8 million in 2025, with projected growth to USD 59.0 million by 2030, representing a steady CAGR of 5.6% over the forecast period.

Healthcare Infrastructure Investment :

Significant government and private sector investments in KSA's healthcare infrastructure are driving biobanking adoption, supported by Vision 2030 initiatives focused on advanced medical technologies and research capabilities.

Chronic Disease Prevalence :

Rising incidence of chronic diseases including diabetes, cardiovascular conditions, and cancer in KSA is creating increased demand for biobanking services to support diagnostic and treatment research.

Precision Medicine Adoption :

Growing implementation of precision medicine and personalized healthcare approaches across KSA's medical institutions is accelerating the need for sophisticated biobanking infrastructure and sample management solutions.

Ksa Biobanking Market Dynamics

  • The Kingdom's commitment to diversifying its economy and advancing medical sciences through Vision 2030 is creating favorable conditions for biobanking infrastructure development.
  • Investment in hospital networks, research centers, and diagnostic facilities continues to strengthen the market foundation. The market will benefit from growing partnerships between KSA's healthcare institutions and international research organizations, coupled with rising awareness of personalized medicine benefits.
  • Regulatory frameworks supporting biobanking operations and sample management are becoming more established, enabling market players to expand service offerings.
  • By 2030, KSA's biobanking sector is expected to play a critical role in supporting the Kingdom's broader healthcare transformation and research ecosystem development..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Ksa's biobanking market is valued at USD 44.8 million in 2025 and will reach USD 59.0 million by 2030, growing at 5.6% CAGR.
    • Ksa is experiencing strong government backing for life sciences research, creating favorable conditions for biobanking infrastructure development.
    • Clinical trial expansion and precision medicine adoption are key growth drivers accelerating biobanking demand across Ksa.
    • Ksa's biobanking sector benefits from enhanced regulatory frameworks and public-private healthcare collaborations within the GCC region.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Ksa Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    KINGDOM OF SAUDI ARABIA (KSA): BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES5.35.35.666.56.97.587.3
    HOSPITALS & DIAGNOSTIC LABORATORIES3.33.33.53.744.34.64.96.9
    PHARMA-BIOTECH COMPANIES & CROS12.712.913.614.615.716.918.219.77.6
    TOTAL21.321.522.824.426.128.130.232.67.4

    KINGDOM OF SAUDI ARABIA (KSA): BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS33.633.634.936.638.640.843.446.25.8
    CROS9.79.69.910.310.811.41212.75.1
    TOTAL43.343.344.846.949.452.255.4595.6

    Target Audience

    • Healthcare Providers & Hospital Networks : KSA hospital systems and medical centers need market intelligence to evaluate biobanking service integration, understand competitive positioning, and plan infrastructure investments aligned with market growth trends.
    • Biobanking Service Providers : Biobanking companies and laboratory operators require KSA-specific market data to assess expansion opportunities, identify customer segments, and develop localized service offerings for the Kingdom's healthcare institutions.
    • Research & Academic Institutions : Universities and research centers in KSA need market insights to understand biobanking capabilities, identify collaboration opportunities, and secure funding for precision medicine and genomic research initiatives.
    • Healthcare Investors & Private Equity : Investment firms targeting KSA's healthcare sector require detailed market analysis to evaluate biobanking investment opportunities, assess growth potential, and identify acquisition or partnership targets.
    • Government & Healthcare Policy Makers : KSA's health ministry and policy officials need market data to inform healthcare infrastructure planning, regulatory framework development, and alignment of biobanking initiatives with Vision 2030 objectives.

    Key Companies in the Ksa Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Market-Specific Growth Projections : Access detailed KSA-specific forecasts showing USD 44.8M (2025) to USD 59M (2030) growth trajectory, enabling accurate business planning and investment decisions tailored to the Saudi market.
    • Competitive Landscape Intelligence : Understand KSA's unique biobanking ecosystem, including local players, international entrants, and partnership opportunities specific to the Kingdom's healthcare sector dynamics.
    • Regulatory & Infrastructure Insights : Gain comprehensive knowledge of KSA's healthcare regulations, Vision 2030 initiatives, and infrastructure development plans directly impacting biobanking market opportunities and operational requirements.
    • Demand Driver Analysis : Identify KSA-specific factors driving market growth including chronic disease prevalence, precision medicine adoption rates, and government healthcare investment priorities unique to the region.
    • Strategic Market Entry Planning : Develop informed market entry strategies with KSA-focused insights on customer segments, distribution channels, partnership models, and growth acceleration opportunities in the Kingdom.

    Frequently asked questions

    What is the current size of the biobanking market in Ksa?

    The biobanking market in Ksa is estimated at USD 44.8 million in 2025.

    What is the projected market size for biobanking in Ksa by 2030?

    Ksa's biobanking market is projected to reach USD 59.0 million by 2030.

    What is the CAGR for biobanking in Ksa from 2025 to 2030?

    The biobanking market in Ksa is expected to grow at a CAGR of 5.6% during the 2025–2030 forecast period.

    What are the main drivers of biobanking growth in Ksa?

    Key growth drivers in Ksa include increased healthcare infrastructure investment, rising chronic disease prevalence, precision medicine adoption, clinical trial expansion, and government support for life sciences research.

    How does Ksa's biobanking market compare to other GCC countries?

    Ksa is a leading player in the GCC biobanking landscape, supported by strong government initiatives, regulatory frameworks, and public-private healthcare collaborations that position it favorably within the regional market.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status